166 related articles for article (PubMed ID: 37928523)
1. IGFBP2 from a novel copper metabolism-associated biomarker promoted glioma progression and response to immunotherapy.
Luo Q; Zhuang J; Zheng D; Miao C; Luo H; Peng J; Zheng C; Qin C; Lan C; Chen M; Xia Y; Huang D; Chen Z
Front Immunol; 2023; 14():1282734. PubMed ID: 37928523
[TBL] [Abstract][Full Text] [Related]
2. RUNX1/CD44 axis regulates the proliferation, migration, and immunotherapy of gliomas: A single-cell sequencing analysis.
Zhang H; Cao H; Luo H; Zhang N; Wang Z; Dai Z; Wu W; Liu G; Xie Z; Cheng Q; Cheng Y
Front Immunol; 2023; 14():1086280. PubMed ID: 36776876
[TBL] [Abstract][Full Text] [Related]
3. Relevance of IGFBP2 proteolysis in glioma and contribution of the extracellular protease ADAMTS1.
Martino-Echarri E; Fernández-Rodríguez R; Bech-Serra JJ; Plaza-Calonge Mdel C; Vidal N; Casal C; Colomé N; Seoane J; Canals F; Rodríguez-Manzaneque JC
Oncotarget; 2014 Jun; 5(12):4295-304. PubMed ID: 24962328
[TBL] [Abstract][Full Text] [Related]
4. IGFBP2 expression predicts IDH-mutant glioma patient survival.
Huang LE; Cohen AL; Colman H; Jensen RL; Fults DW; Couldwell WT
Oncotarget; 2017 Jan; 8(1):191-202. PubMed ID: 27852048
[TBL] [Abstract][Full Text] [Related]
5. Glioma progression is mediated by an addiction to aberrant IGFBP2 expression and can be blocked using anti-IGFBP2 strategies.
Phillips LM; Zhou X; Cogdell DE; Chua CY; Huisinga A; R Hess K; Fuller GN; Zhang W
J Pathol; 2016 Jul; 239(3):355-64. PubMed ID: 27125842
[TBL] [Abstract][Full Text] [Related]
6. Multicellular gene network analysis identifies a macrophage-related gene signature predictive of therapeutic response and prognosis of gliomas.
Sun X; Liu X; Xia M; Shao Y; Zhang XD
J Transl Med; 2019 May; 17(1):159. PubMed ID: 31097021
[TBL] [Abstract][Full Text] [Related]
7. The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma.
Wang W; Lu Z; Wang M; Liu Z; Wu B; Yang C; Huan H; Gong P
Front Immunol; 2022; 13():998236. PubMed ID: 36110851
[TBL] [Abstract][Full Text] [Related]
8. RAB34 was a progression- and prognosis-associated biomarker in gliomas.
Wang HJ; Gao Y; Chen L; Li YL; Jiang CL
Tumour Biol; 2015 Mar; 36(3):1573-8. PubMed ID: 25501506
[TBL] [Abstract][Full Text] [Related]
9. Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples.
Cai J; Chen Q; Cui Y; Dong J; Chen M; Wu P; Jiang C
Oncoimmunology; 2018; 7(5):e1426516. PubMed ID: 29721393
[TBL] [Abstract][Full Text] [Related]
10. Identification of a copper metabolism-related gene signature for predicting prognosis and immune response in glioma.
Li L; Leng W; Chen J; Li S; Lei B; Zhang H; Zhao H
Cancer Med; 2023 Apr; 12(8):10123-10137. PubMed ID: 36856182
[TBL] [Abstract][Full Text] [Related]
11. Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas.
Ye L; Tong S; Wang Y; Wang Y; Ma W
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9857-9876. PubMed ID: 37248320
[TBL] [Abstract][Full Text] [Related]
12. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
13. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
Li J; Zhang Y; Qu Z; Ding R; Yin X
Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
[TBL] [Abstract][Full Text] [Related]
14. IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas.
Moore LM; Holmes KM; Smith SM; Wu Y; Tchougounova E; Uhrbom L; Sawaya R; Bruner JM; Fuller GN; Zhang W
Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16675-9. PubMed ID: 19805356
[TBL] [Abstract][Full Text] [Related]
15. GPX8 regulates pan-apoptosis in gliomas to promote microglial migration and mediate immunotherapy responses.
Chen Z; Zheng D; Lin Z; Zhang C; Wei C; Deng X; Yan P; Zheng C; Lan C; Qin C; Wei X; Qin D; Wu Y; Peng J; Miao C; Lu L; Xia Y; Luo Q
Front Immunol; 2023; 14():1260169. PubMed ID: 37795080
[TBL] [Abstract][Full Text] [Related]
16. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive characterization of TNFSF14/LIGHT with implications in prognosis and immunotherapy of human gliomas.
Han M; Sun Y; Zhao W; Xiang G; Wang X; Jiang Z; Xue Z; Zhou W
Front Immunol; 2022; 13():1025286. PubMed ID: 36341396
[TBL] [Abstract][Full Text] [Related]
18. PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas.
Zhang H; He J; Dai Z; Wang Z; Liang X; He F; Xia Z; Feng S; Cao H; Zhang L; Cheng Q
Front Immunol; 2021; 12():628966. PubMed ID: 33664747
[TBL] [Abstract][Full Text] [Related]
19. Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment.
Zhang N; Zhang H; Wang Z; Dai Z; Zhang X; Cheng Q; Liu Z
Front Immunol; 2021; 12():691811. PubMed ID: 34489938
[TBL] [Abstract][Full Text] [Related]
20. Single cell RNA sequencing reveals differentiation related genes with drawing implications in predicting prognosis and immunotherapy response in gliomas.
Zhou Z; Wei J; Yang Z; Bao Y; Jiang W; Lu B; Wang W; Li L
Sci Rep; 2022 Feb; 12(1):1872. PubMed ID: 35115572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]